The new monoclonal antibody treatment location at the Mangilao Senior Center has opened its doors.
According to Cpt. Mark Scott, Guam Guard public information officer, in order for individuals to be able to receive the antibody treatment, they must be referred to the center by a health care provider and they should be from medium to high risk of being affected by COVID.
“Some of those conditions include being positive for COVID, being symptomatic, being of a certain age, being unvaccinated. Those things all increase the risk of severe infection, which this monoclonal antibody treatment is designed to protect against,” Scott said.
When asked how the antibodies are administered to patients, Scott says the treatment is given through a shot.
“The treatment that we’re doing here is called subcutaneous which in other words means a shot. It’s not an IV … there’s 2 ways to administer this, the IV and the subcutaneous, this will be subcutaneous. It should just take a few minutes. But after the few minutes of the injections is an hour-long observation period to make sure that there’s no adverse side effects,” Scott said.
He added that patients will receive aftercare instructions once the procedure is finished and are free to go home. However, if the patients, who are COVID-positive, are not safe or do not feel safe to quarantine and isolate at home, DPHSS can be called to assist in transferring the patient to a government isolation facility.
In addition, the treatment is not limited to those who are unvaccinated. Scott says that even those who are vaccinated can receive the treatment, but reiterates that they must be referred by their care provider or at the Tiyan testing site.
“So it’s not that vaccinated people can’t avail of the treatment. It’s really up to the provider to make the referral. So if you get tested with your provider and get that recommendation, they refer you to this clinic. So the decision is really on your provider to decide if you’re high risk and should come to this treatment,” Scott said.
PNC’s Don Sulat has more details …